Want to see ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
$116.52
$2.30(1.83%)
At close: 4:00 PM EDT
$116.52
$2.30(1.83%)
Day’s Range― - ―
52-Week Range$69.81 - $148.83
Previous Close$127
Volume662.35K
Average Volume (3M)1.31M
Market Cap
$7.77B
Enterprise Value$10.16B
Total Cash (Recent Filing)$410.68M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta3.08
Next Earnings
Dec 14, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.57
Shares Outstanding87,548,100
10 Day Avg. Volume1,216,907
30 Day Avg. Volume1,308,438
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)17.54
Price to Sales (P/S)0.00
P/FCF Ratio-51.21
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-26.80
Forecast
1Y Price Target
$156.43Price Target Upside34.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.28
Revenue Forecast (FY)$4.43M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 Maintenance DataPositive Phase 3 maintenance results in refractory ulcerative colitis broaden the clinical evidence base beyond the core registrational population. The remission and retreatment findings support obefazimod's potential for durable disease control and could strengthen commercial positioning if regulatory review succeeds.
Substantial Funding RaisedThe sizeable equity raise materially increases financial flexibility for continued clinical development and planned commercialization activities. A stronger funding base can reduce near-term financing pressure, support execution through regulatory milestones, and provide resources for building the organization around a potential launch.
Low Financial LeverageVery low leverage gives Abivax greater balance-sheet flexibility while it funds a loss-making clinical and potential commercial transition. Limited debt obligations reduce fixed financial pressure and allow more of its capital base to support research, regulatory preparation, and operating infrastructure.
Bears Say
Zero Revenue And Widening LossesThe absence of current revenue and sharply widening losses show that Abivax has not yet established a commercial earnings base. Continued dependence on development funding leaves results highly sensitive to clinical and regulatory execution, while persistent losses can erode equity over time.
Heavy Ongoing Cash BurnLarge operating and free-cash-flow deficits indicate substantial ongoing funding needs as Abivax advances its programs. Even with improved financing resources, sustained cash consumption can require future capital raises and may constrain the pace or scope of development and commercialization investment.
Chief Medical Officer TransitionThe planned departure of the Chief Medical Officer introduces a leadership transition during an important period of late-stage development and potential commercialization. Although a successor has been appointed, changing senior medical leadership can create execution and continuity risk across regulatory and launch preparation.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $69.81 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $7.77B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Dec 14, 2026 which is in 57 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on Sep 21, 2026. The company reported -$1.682 earnings per share for the quarter, missing the consensus estimate of -$0.917 by -$0.765.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.96.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 87,548,100 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$1.682 in its last earnings report, missing expectations of -$0.917. Following the earnings report the stock price went down -4.988%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$156.43 (34.25% Upside)
$156.43 (34.25% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 85%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.14%
12-Months-Change
Fundamentals
Return on Equity
-85.88%
Trailing 12-Months
Asset Growth
276.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abivax SA Sponsored ADR
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$156.43
▲(34.25% Upside)
Technical Analysis
Ownership Overview
―
Insiders
5.45% Mutual Funds
0.86% Other Institutional Investors
92.67% Public Companies and
Individual Investors